Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Mike Ward
While GSK and collaborators publish findings from the IMPACT trial comparing once-daily single-inhaler triple versus dual therapy in patients with COPD in NEJM, two clinicians in an accompanying editorial argue that the trial falls short of providing robust evidence for switching strategy.
Denoive acquires from TVM Capital both Biovertis and Morphochem, plus a Phase II ready antibiotic asset, for an initial 4% stake worth €900,000. Since their formation, Biovertis and Morphochem have had more than $96m invested in them.
At a pre-money valuation of $2bn, BenevolentAI raises $115m to develop artificial intelligence approach that already can cut early drug development timeline by four years.
French pharma Servier takes step to meet its strategic ambition of becoming a global player in oncology by acquiring Shire's cancer franchise for $2.4bn
Cellectis, the French clinical-stage biopharma focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells, will receive $164m from its underwritten offering of 5,646,000 American Depositary Shares at $31 per ADS. The lion’s share of the funds is earmarked to create the infrastructure to commercialize its immuno-oncology UCART product candidates.
BioNTech AG raised $270m in a series A venture round at the start of 2018 as it pursues an ambition to create a fully integrated biopharmaceutical company. COO Sean Marett tells Scrip how the funds will be invested.